IDH1 Non-Canonical Mutations and Survival in Patients with Glioma
Enrico Franceschi,
Dario De Biase,
Vincenzo Di Nunno,
Annalisa Pession,
Alicia Tosoni,
Lidia Gatto,
Giovanni Tallini,
Michela Visani,
Raffaele Lodi,
Stefania Bartolini,
Alba Ariela Brandes
Affiliations
Enrico Franceschi
Department of Oncology, AUSL Bologna, 40139 Bologna, Italy
Dario De Biase
Department of Pharmacy and Biotechnology (Dipartimento di Farmacia e Biotecnologie), Molecular Diagnostic Unit, Azienda USL di Bologna, University of Bologna, 40126 Bologna, Italy
Vincenzo Di Nunno
Department of Oncology, AUSL Bologna, 40139 Bologna, Italy
Annalisa Pession
Department of Pharmacy and Biotechnology (Dipartimento di Farmacia e Biotecnologie), Molecular Diagnostic Unit, Azienda USL di Bologna, University of Bologna, 40126 Bologna, Italy
Alicia Tosoni
Department of Oncology, AUSL Bologna, 40139 Bologna, Italy
Lidia Gatto
Department of Oncology, AUSL Bologna, 40139 Bologna, Italy
Giovanni Tallini
Department of Medicine (Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale), Molecular Diagnostic Unit, Azienda USL di Bologna, University of Bologna School of Medicine, 40126 Bologna, Italy
Michela Visani
Department of Medicine (Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale), Molecular Diagnostic Unit, Azienda USL di Bologna, University of Bologna School of Medicine, 40126 Bologna, Italy
Raffaele Lodi
IRCCS Istituto delle Scienze Neurologiche di Bologna, 40139 Bologna, Italy
Stefania Bartolini
Department of Oncology, AUSL Bologna, 40139 Bologna, Italy
Alba Ariela Brandes
Department of Oncology, AUSL Bologna, 40139 Bologna, Italy
Background: Non-canonical mutations of the isocitrate dehydrogenase (IDH) genes have been described in about 20–25% and 5–12% of patients with WHO grade II and III gliomas, respectively. To date, the prognostic value of these rare mutations is still a topic of debate. Methods: We selected patients with WHO grade II and III gliomas and IDH1 mutations with available tissue samples for next-generation sequencing. The clinical outcomes and baseline behaviors of patients with canonical IDH1 R132H and non-canonical IDH1 mutations were compared. Results: We evaluated 433 patients harboring IDH1 mutations. Three hundred and ninety patients (90.1%) had a canonical IDH1 R132H mutation while 43 patients (9.9%) had a non-canonical IDH1 mutation. Compared to those with the IDH1 canonical mutation, patients with non-canonical mutations were younger (p p = 0.017). Multivariate analysis confirmed that the extension of surgery (p = 0.003), the presence of the 1p19q codeletion (p = 0.001), and the presence of a non-canonical mutation (p = 0.041) were variables correlated with improved overall survival. Conclusion: the presence of non-canonical IDH1 mutations could be associated with improved survival among patients with IDH1 mutated grade II–III glioma.
